+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment

Clinical Infectious Diseases 40(5): 728-734

Background. For patients with human immunodeficiency virus (HIV) infection, structured treatment interruption (STI) is an attractive alternative strategy to continuous treatment, particularly in resource-restrained settings, because it reduces both side effects and costs. One major concern, however, is the development of resistance to antiretroviral drugs that can occur during multiple cycles of starting and stopping therapy. Methods. HIV genotypic drug resistance was investigated in 20 HIV-infected Thai patients treated with highly active antiretroviral therapy (HAART) and CD4 cell count-guided STI after dual nucleoside reverse-transcriptase inhibitor (NRTI) treatment. Resistance was tested at the time of the switch from dual-NRTI treatment to HAART and when HAART was stopped during the last interruption. Results. After STI, one major drug-resistance mutation occurred (T215Y), and, in the 4 samples with preexisting major mutations (D67N (n = 2), K70R (n = 2), T215Y (n = 2), and T215I (n = 1)), the mutations disappeared. All mutations in the HIV protease gene were minor mutations already present, in most cases, before STI was started, and their frequency was not increased through STI, whereas the frequency of reverse-transcriptase gene mutations significantly decreased after the interruptions. After the 48-week study period, no patients had virological failure. Long-term follow-up (108 weeks) showed 1 case of virological failure in the STI arm and 1 in the continuous arm. No virological failure was seen in patients with major mutations. Conclusions. Major HIV drug-resistance mutations were not induced through CD4 cell count-guided treatment interruptions in HIV-infected patients successfully treated with HAART after dual-NRTI therapy.

(PDF emailed within 0-6 h: $19.90)

Accession: 011943867

Download citation: RISBibTeXText

PMID: 15714420

DOI: 10.1086/427878

Related references

CD4+cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS (Hagerstown) 18(18): 2381-2389, 2004

Dual nucleoside analogue treatment in the era of highly active antiretroviral therapy (HAART): a single-centre cross-sectional survey. Journal of Antimicrobial ChemoTherapy 48(2): 299-302, 2001

CD4+ T-cell-guided structured treatment interruptions of antiretroviral therapy in HIV disease: projecting beyond clinical trials. Antiviral Therapy 15(3): 351-361, 2010

Study on the effect of treatment and the status of drug resistance among HIV/AIDS patients treated with highly active antiretroviral therapy in Shandong province. Zhonghua Liu Xing Bing Xue Za Zhi 28(11): 1108-1111, 2008

Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral-experienced patients preserves viral benefit when a fully active therapy was initiated. HIV Clinical Trials 9(6): 387-398, 2009

Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. Journal of Infectious Diseases 188(10): 1426-1432, 2003

The paradox of incomplete CD4+ cell count restoration despite successful antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clinical Infectious Diseases 48(6): 795-797, 2009

Long-term persistence of HIV with drug resistance after CD4 cell count-guided structured treatment interruption. Aids 19(15): 1713-1714, 2005

Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. Aids 18(2): 237-245, 2004

Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. Journal of Infectious Diseases 197 Suppl 3: S261-S271, 2008

Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy. Zhonghua Liu Xing Bing Xue Za Zhi 29(8): 794-800, 2009

Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy. Aids 15(17): 2325-2327, 2001

Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. Aids Patient Care and Stds 22(7): 545-552, 2008

Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines. Journal of Acquired Immune Deficiency Syndromes 53(4): 544-546, 2010

Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance. Aids 15(7): 941-943, 2001